Database Chemabs [Online] Chemical Abstracts Service, Columbus, Ohio, U.S. Udvardy, M. Et al: “RDGFAP:platelet aggregation inhibitory and profibrinolytic hybrid peptid (RGDF coupled with the carboxy terminal part of alpha.2-antiplasmin) enhances plasminogen binding to platelets” retrieved from STN Database accession No. 123:218018 XP002124573 abstract & Blood Coagulation Fibrinolysis (1995), 6(5), 481-5. |
Butte et al., “A2-Antiplasmin Causes Thrombi to Resist Fibrinolysis Induced by Tissue Plasminogen Activator in Experimental Pulmonary Embolism”, Circulation, vol. 95, No. 7, Apr. 1, 1997. |
Lincoff et al., “Significance of a Coronary Artery With thrombolysis in Myocardial Infarction Grade 2 Flow Patency . . . ”, The American Journal of Cardiology, vol. 75, May 1, 1995. |
Karagounis et al., “Does Thrombolysis in Myocardial Infarction (TIMI) Perfusion Grade 2 Represent a Mostly Patent or a Mostly . . . ”, JACC vol. 19, No. 1, Jan. 1992:1-10. |
Salzman et al., “The epidemiology, pathogenesis and natural history of venous thrombosis, in Hemostasis . . . ”, Basic Principles and Clinical Practice, 3rd ed., Philadelphia, PA, Lippincott, pp 1275-1296. |
Goldhaber et al., “Randomized Controlled Trial of Tissue Plasminogen Activator in Proximal Deep Venous . . . ”, 1990, Am J. Med. 88:235-240. |
A Natural Cooperative Study, Circulation, Apr. 1973;47(2 Supp):II1-108, “The urokinase pulmonary embolism trial.” |
Goldhaber et al., “Acute Pulmonary Embolism Treated With Tissue Plasminogen Activator”, 986, Lancet 2:886-889. |
Rampling et al., “The Sulphite Precipitation Method for Fibrinogen Measurement; Its Use on Small . . . ”, 1976, Clin. Chim. Acta. 67:43-52. |
Ichinose et al., Factor XIII-mediated cross-linking of NH2-terminal peptide of a2-plasmin inhibitor to fibrin, 1983, FEBS Letters 153:369-371. |
Okada et al., “Effects of Fibrin and a2-Antiplasmin on Plasminogen Activation by Staphylokinase”, American Journal of Hematology 53:151-157 (1996). |
Schaefer et al., “a2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds”, Arch Dermatol Res (1996) 288:122-128. |
Reed G., “Functional Characterization of Monoclonal Antibody Inhibitors of a2-Antiplasmin that Accelerate . . . ”, Hybridoma, vol. 16, No. 3, pp. 281-286 (1997). |
Colucci et al, “In Vitro Clot Lysis as a Potential Indicator of Thrombus Resistance to Fibrinolysis . . . ”, Thrombosis and Haemostasis, vol. 77 No. 4 pp. 610-807, Apr. 1997. |
Duboscq et al., “Plasminogen: An Important Hemostatic Parameter in Septic Patients”, Throm. Haemost. 1997; 77:1090-5. |
Udvardy, M. et al. (1995) “Platelet Aggregation Inhibitory and Profibrinolytic Hybrid Peptid (RGDF coupled with the Carboxy Terminal Part of Alpha.2-antiplasmin) Enhances Plasminogen Binding To Platelets” Abstract XP002124573. |
Udvardy, M. et al: RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptid (RDGF coupled with the carboxy terminal part of.alpha.2-antiplasmin) enhances plasminogen binding to platelets Blood Coagulation Fibrinolysis (1995), 6(5), 481-5 (abstract only). |